Hongliang Liu

Hongliang Liu

Auto-generated profile, based on publicly available information

Hongliang Liu

Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, PR China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
HLHongliang Liu
Hongliang Liu
YZYu Zhang
Yu Zhang
LLLi Li
Li Li
JCJimin Cao
Jimin Cao
YGYujia Guo
Yujia Guo
WGWei Gao
Wei Gao
Fascin actin-bundling protein 1 (FSCN1) is a highly conserved actin-bundling protein that cross links F-actin microfilaments into tight, parallel bundles. Elevated FSCN1 levels have been reported in many types of human cancers and have been correlated with aggressive clinical progression, poor prognosis, and survival outcomes. The overexpression of FSCN1 in cancer cells has been associated with tumor growth, migration, invasion, and metastasis. Currently, FSCN1 is recognized as a candidate biomarker for multiple cancer types and as a potential therapeutic target. The aim of this study was to provide a brief overview of the FSCN1 gene and protein structure and elucidate on its actin-bundling activity and physiological functions. The main focus was on the role of FSCN1 and its upregulatory mechanisms and significance in cancer cells. Up-to-date studies on FSCN1 as a novel biomarker and therapeutic target for human cancers are reviewed. It is shown that FSCN1 is an unusual biomarker and a potential therapeutic target for cancer.

12 July 2019 in IUBMB Life
Verified
Journal Article
Open access
PDF file
HLHongliang Liu
Hongliang Liu
JCJiajia Cui
Jiajia Cui
YZYuliang Zhang
Yuliang Zhang
MNMin Niu
Min Niu
XXXuting Xue
Xuting Xue
WGWei Gao
Wei Gao
Fascin actin‐bundling protein 1 (FSCN1) is an evolutionarily conserved actin‐bundling protein that plays a critical role in cell migration, motility, adhesion, and cellular interactions. Although multiple clinical studies have implicated the expression of FSCN1 in laryngeal squamous cell carcinoma (LSCC) progression, the precise mechanism of FSCN1 in the process has not been clearly elucidated. To define FSCN1 function, we characterized FSCN1‐interacting proteins in LSCC cells by immunoprecipitation followed by mass spectrometry (MS). After data filtering, 119 proteins with expression in both the Hep‐2 and TU‐177 cell samples were identified as FSCN1‐interacting partners. With in‐depth bioinformatics analysis, we linked FSCN1 to critical cellular processes including cell adhesion, glycolysis/gluconeogenesis, regulation of protein ubiquitination, ribosomal RNA processing, and small molecule metabolism. We discuss the interactions between FSCN1 and some of the newly validated partners. The identification of these potential partners of FSCN1 expands our knowledge of the FSCN1 interactome and provides a valuable resource for understanding the functions of this protein in LSCC progression.

18 July 2019 in IUBMB Life
Verified
Journal Article
Open access
PDF file
XYXiaoyi Yu
Xiaoyi Yu
YLYingzi Luo
Yingzi Luo
GCGangyi Chen
Gangyi Chen
HLHong Liu
Hong Liu
NTNi Tian
Ni Tian
QLQiuhong Liu
Qiuhong Liu
High‐glucose‐induced retinal tissue impairment is the major pathological phenotype of diabetic retinopathy. In an in vitro diabetic apoptosis cell model, we evaluated the function of long noncoding RNA, insulin growth factor 2 antisense (IGF2‐AS) in high‐glucose‐injured human retinal pigment epithelial cells. A human retinal pigment epithelial cell line, ARPE‐19 was incubated with high‐glucose in vitro to induce apoptosis. SiRNA‐mediated IGF2‐AS downregulation was conducted in ARPE‐19 cells to evaluate its effect on high‐glucose induced apoptosis, assessed by a TUNEL assay. qRT‐PCR and western blot assays were applied to examine the functional effect of IGF2‐AS on IGF2/AKT/Casp‐9 expressions in glucose‐injured ARPE‐19 cells. ART was further knocked down, specifically in IGF2‐AS‐downregualted ARPE‐19 cells, to investigate its functional involvement in IGF2‐AS‐inhibition‐mediated apoptotic protection in glucose‐injured ARPE‐19 cells. High‐glucose induced apoptosis in ARPE‐19 cells, and upregulated IGF‐2AS in a dose‐dependent manner. SiRNA‐mediated IGF2‐AS downregulation ameliorated apoptosis, upregulated IGF2/AKT and decreased Casp‐9, in high‐glucose‐treated ARPE‐19 cells. AKT knockdown was shown to dramatically reverse the preventive effect of IGF2‐AS‐downregulation on high‐glucose‐induced apoptosis in ARPE‐19 cells. Moreover, it was demonstrated that AKT knockdown directly upregulated Casp‐9 in IGF2‐AS‐downregulated and high‐glucose‐treated ARPE‐19 cells. We demonstrated that inhibiting IGF2‐AS, possibly also through activation of AKT signaling pathway, has a protective function in high‐glucose‐induced apoptosis in human retinal pigment epithelial cells in diabetic retinopathy.